Skip to content

    Concord Biotech

    CONCORDBIOGood
    Healthcare·30 May 2025
    Management Summary

    Concord Biotech delivered a strong finish to FY25, characterized by significant revenue acceleration in Q4 and disciplined margin management. The company is successfully diversifying its portfolio away from heavy immunosuppressant reliance (now 74% of revenue) toward anti-infectives and high-potential injectables. Management is pivoting toward a CDMO model and targeting a long-term 25% CAGR, supported by newly commissioned capacities and a robust ANDA/DMF pipeline.

    Highlights

    7

    • Full year FY25 revenue reached ₹1,200 crores, representing 18% YoY growth.

    • Q4 FY25 revenue grew 35% YoY to ₹430 crores, driven by strong API and formulation performance.

    • Full year PAT stood at ₹372 crores, a 21% YoY increase with a 31% PAT margin.

    • EBITDA for FY25 grew 17% to ₹506 crores, with Q4 EBITDA margins at a robust 44.3%.

    • Commissioned a state-of-the-art injectable facility at Valthera with a potential turnover capacity of ₹600 crores.

    • API business grew 14% for the full year to ₹940 crores; Formulation business grew 38% to ₹260 crores.

    • Received US FDA approval for Teriflunomide tablets (ANDA) and filed 2 new DMFs for Nystatin and Voclosporin.

    Key financials

    Single quarter

    05 metrics
    1. 01Revenue₹1,200 Cr+18%YoY
    2. 02EBITDA₹506 Cr+17%YoY
    3. 03EBITDA Margin42.2%
    4. 04PAT₹372 Cr+21%YoY
    5. 05PAT Margin31%

    Segment breakdown

    • API₹940 Cr78.3%
    • Formulation₹260 Cr21.7%
    Donut· Share of Revenue

    Guidance & targets

    4
    CategoryTargetPriority
    Revenue
    Long-term CAGR Growth
    25%
    		Medium
    Capacity
    Injectable Facility Turnover Potential
    ₹600 crores
    		High
    Market Share
    Teriflunomide US Market Share
    10-15%
    		Medium
    Capex
    Maintenance Capex
    ₹20-30 crores
    		High

    Risks & concerns

    5
    RiskSeverity

    US FDA Regulatory Observations

    Dholka Unit 1 received 483 observations; management claims they are procedural and not related to data integrity. — Management acknowledged

    medium

    Gross Margin Volatility

    Sequential compression in gross margins due to product mix and internal transfer pricing dynamics. — Analyst acknowledged

    medium

    Lumpy Quarterly Performance

    Management noted that procurement patterns can lead to uneven quarterly revenue, making full-year analysis more reliable. — Management acknowledged

    low

    Areas of Evasion(2)

    • Specific therapy-level revenue data beyond immunosuppressants.
    • Exact timeline for the CDMO business reaching double-digit contribution.

    Q&A highlights

    3

    “This could be on account of change in the product mix... our API products, which are being transferred to formulation units happen at a market price and all the sales get booked in the formulation business.”

    Explains the 8% sequential dip in gross margins as a function of internal transfer pricing and product mix rather than fundamental pricing pressure.

    asked by Manoj Bahety, Carnelin Asset Management

    2 min read5 chapters

    Detailed Narrative

    01

    Injectable Facility as the Next Growth Engine

    Concord Biotech successfully commissioned its injectable facility at Valthera (Unit 4) in March 2025. Management highlighted that this state-of-the-art unit has the capacity to generate approximately ₹600 crores in annual turnover at full utilization. While revenue contribution will begin in FY26, a full ramp-up is expected over FY27 and FY28, providing a significant runway for the formulation segment which currently contributes only 22% of total revenue.

    02

    Strategic Pivot Toward CDMO and Diversification

    The company is actively transitioning from a pure-play API manufacturer to an integrated CDMO partner. Although CDMO currently accounts for less than 1% of revenue, management has commercialized one project with an innovator and is in advanced discussions for 3-4 more. The goal is to move CDMO to a double-digit revenue contributor. Simultaneously, the share of immunosuppressants has dropped from 80% to 74% as anti-infectives gain traction.

    03

    Regulatory Compliance and Global Expansion

    Regulatory milestones were a key theme, with the API facility at Dholka Unit 1 undergoing a US FDA inspection. While it resulted in 483 observations, management emphasized these were procedural and they expect an EIR shortly. Furthermore, the Valthera facility received an EU GMP certificate, and the company secured ANDA approval for Teriflunomide, targeting a 10-15% share of a $402 million US market.

    04

    Margin Dynamics and Operational Efficiency

    Despite a sequential dip in gross margins in Q4, EBITDA margins remained strong at 44.3% for the quarter and 42.2% for the year. Management explained that internal transfers of API to the formulation unit at market prices can optically compress gross margins but are neutral at the EBITDA level. The company added 118 new customers in FY25, enhancing its operating leverage and reducing dependency on any single client.

    05

    Sustainability and ESG Integration

    Concord made a strategic investment in Clean Max, a renewable energy company, to power its Dholka plant with wind and solar energy. This initiative is expected to significantly reduce the company's carbon footprint while providing long-term financial benefits through lower energy costs. This move aligns with their broader commitment to ESG principles as they scale global operations.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.